Prellis Biologics
Harnessing human diversity and AI to build next-generation medicines
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- prellisbio.com
- Total Funding
- $49.5M
- Last Round
- $35.0M Series CAug 2022
- Rounds
- 2
About
Prellis Biologics is a pre-IPO biotech company that harnesses AI and human immune diversity to develop next-generation antibody therapeutics. Its EXIS (Externalized Immune System) platform combines holographic bioprinting, fully human antibody discovery, and tightly integrated machine learning to identify antibody candidates from the full human immune repertoire with unparalleled speed and precision. The company partners with pharmaceutical companies to advance drug discovery across metabolic disease, inflammation, and oncology.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Aug 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...